The protective roles of augmenter of liver regeneration in hepatocytes in the non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) occurs in 25% of the global population and manifests as lipid deposition, hepatocyte injury, activation of Kupffer and stellate cells, and steatohepatitis. Predominantly expressed in hepatocytes, the augmenter of liver regeneration (ALR) is a key factor in l...
Main Authors: | Yuan Dong, Yuejie Zhang, Yingmei Feng, Wei An |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.928606/full |
Similar Items
-
Alcohol? Not for Non-alcoholic Fatty Liver Disease Patients
by: Francesca Cainelli, et al.
Published: (2020-02-01) -
Diagnostic accuracy of FibroScan-AST (FAST) score, non-alcoholic fatty liver fibrosis score (NFS), FibroScan, and liver fibrosis index (FIB-4) for identifying fibrotic non-alcoholic steatohepatitis in patients with chronic hepatitis B with metabolic dysfunction-associated fatty liver disease
by: Youwen Tan, et al.
Published: (2024-12-01) -
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis
by: Maryam Mahjoubin-Tehran, et al.
Published: (2021-08-01) -
Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
by: Daryl Ramai, et al.
Published: (2021-12-01) -
Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients
by: Yan Huang, et al.
Published: (2022-01-01)